{"transactions":[{"id":1886540,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-05-18T22:19:49.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":63567,"price":1.068,"value":67889.556,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted \"sell-to-cover\" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on June 8, 2022."}],"balance_after":446483,"source":{"system":"sec-edgar","filing":"0001562180-23-004253","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023004253/primarydocument.xml","form_type":"4"}},{"id":1971965,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-03-03T13:00:54.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":810,"price":0.8775,"value":710.775,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":510050,"source":{"system":"sec-edgar","filing":"0001562180-23-002197","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002197/primarydocument.xml","form_type":"4"}},{"id":1971964,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-03-03T13:00:54.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":6400,"price":0.8775,"value":5616.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."}],"balance_after":510860,"source":{"system":"sec-edgar","filing":"0001562180-23-002197","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002197/primarydocument.xml","form_type":"4"}},{"id":1983107,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-03-01T21:05:50.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":7539,"price":0.8132,"value":6130.7148,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."}],"balance_after":517260,"source":{"system":"sec-edgar","filing":"0001562180-23-002038","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002038/primarydocument.xml","form_type":"4"}},{"id":2035282,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-02-02T21:14:48.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":294300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":294300,"derivative":{"exercise_price":0.63,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":294300},"source":{"system":"sec-edgar","filing":"0001562180-23-000831","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023000831/primarydocument.xml","form_type":"4"}},{"id":2035281,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-02-02T21:14:48.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":196200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":524799,"source":{"system":"sec-edgar","filing":"0001562180-23-000831","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023000831/primarydocument.xml","form_type":"4"}},{"id":2235494,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Stock Option (Right to buy)","published_at":"2022-06-10T12:11:54.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option to purchase shares of the Issuer's common stock (\"the Stock Option\") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":0.45,"exercise_date":"2023-05-12","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-22-005001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022005001/primarydocument.xml","form_type":"4"}},{"id":2235493,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-06-10T12:11:54.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (the \"RSUs\") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the \"2014 Plan\"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":328599,"source":{"system":"sec-edgar","filing":"0001562180-22-005001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022005001/primarydocument.xml","form_type":"4"}},{"id":2359613,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2022-03-03T02:09:23.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":225000,"derivative":{"exercise_price":2.16,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001562180-22-002160","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002160/primarydocument.xml","form_type":"4"}},{"id":2359612,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-03-03T02:09:23.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":803,"price":2.1707,"value":1743.0721,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":128599,"source":{"system":"sec-edgar","filing":"0001562180-22-002160","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002160/primarydocument.xml","form_type":"4"}},{"id":2359611,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-03-03T02:09:23.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":129402,"source":{"system":"sec-edgar","filing":"0001562180-22-002160","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002160/primarydocument.xml","form_type":"4"}},{"id":2359610,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-03-03T02:09:23.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":7400,"price":2.1548,"value":15945.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."}],"balance_after":69402,"source":{"system":"sec-edgar","filing":"0001562180-22-002160","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002160/primarydocument.xml","form_type":"4"}},{"id":2553985,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-10-01T20:06:55.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.88,"expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-21-006188","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021006188/primarydocument.xml","form_type":"4"}},{"id":2763445,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-04-02T00:34:38.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":790,"price":3.4,"value":2686.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":76802,"source":{"system":"sec-edgar","filing":"0001562180-21-002543","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002543/primarydocument.xml","form_type":"4"}},{"id":2778766,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-03-18T23:19:31.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":7592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards (\"PSUs\") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020.  Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date."}],"balance_after":77592,"source":{"system":"sec-edgar","filing":"0001562180-21-002358","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002358/primarydocument.xml","form_type":"4"}},{"id":2818963,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-03-02T21:05:47.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":3.46,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001562180-21-001767","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001767/primarydocument.xml","form_type":"4"}},{"id":2818962,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-03-02T21:05:47.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001562180-21-001767","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001767/primarydocument.xml","form_type":"4"}},{"id":3090890,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2020-07-02T20:08:39.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest\nover four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":280000,"derivative":{"exercise_price":13.58,"expiration_date":"2030-06-30","underlying":"Common\nStock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000899243-20-018268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924320018268/doc4.xml","form_type":"4"}},{"id":3686684,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-25T21:07:18.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019."}],"balance_after":100000,"derivative":{"exercise_price":3.51,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-19-003415","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919003415/a4.xml","form_type":"4"}},{"id":3996261,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":113343,"kind":"person","name":"Spellman David A","position":1,"cik":"0001733204","reported_name":"Spellman David A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-14T20:49:43.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years."}],"balance_after":150000,"derivative":{"exercise_price":13.97,"expiration_date":"2021-03-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-18-017502","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465918017502/a4.xml","form_type":"4"}}]}